Recombinant Human IGSF4C/SynCAM4 Fc Chimera Protein, CF

Recombinant Human IGSF4C/SynCAM4Fc Chimera (Catalog # 9905-S4) Induces Cortical Neurite Outgrowth.A) Untreated E16-18 embryonic rat cortical neurons. B) Neurite outgrowth inE16-18 embryonic rat cortical neurons treated with 0.5 μg/mL ofRecombinant Human IGSF4C/SynCAM4 Fc Chimera.

2 μg/lane of Recombinant Human IGSF4C was resolved with SDS-PAGEunder reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 74‑97 kDa and 150‑200 kDa,respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IGSF4C/SynCAM4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons. Recombinant Human IGSF4C/SynCAM4 Fc Chimera, immobilized at 0.5-1 μg/mL on a 96-well plate, is able to significantly enhance neurite outgrowth.
• Source: Human embryonic kidney cell, HEK293-derived human IGSF4C/SynCAM4 protein
  

  Human IGSF4C (Gln25-Tyr323) Accession # Q8NFZ8	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q8NFZ8
• N-terminal Sequence: No results obtained. Gln25 inferred from enzymatic pyroglutamate treatment revealing Glu26.
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 60 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 74-97 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 1 mg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IGSF4C/SynCAM4 Fc Chimera Protein, CF

• CADM4
• cell adhesion molecule 4
• IGSF4C
• IGSF4Cnectin-like 4
• Immunoglobulin superfamily member 4C
• immunoglobulin superfamily, member 4C
• Necl-4
• NECL4synCAM4
• Nectin-like protein 4
• SynCAM4
• TSLC1-like 2
• TSLC1-like protein 2
• TSLL2
• TSLL2SynCAM4

Background

IGSF4C is an immunoglobulin superfamily member that is also known as Nectin-like protein 4 (Necl-4), synaptic cell adhesion molecule 4 (SynCAM4), or tumor suppressor in lung cancer-like 2 (TSLL-2) (1, 2). The four IGSF4 proteins, designated A, B, C and D, are type I transmembrane glycoproteins expressed mainly in neurons, but also in lung, kidney, bladder, prostate and testis (1-5). Their extracellular domains (ECD) share 35-50% amino acid (aa) identity and each contain one V-type Ig-like and two C2-type Ig-like domains. These domains are responsible for Ca⁺⁺-independent homophilic and heterophilic interactions. The 388 aa human IGSF4C contains a 20 aa signal sequence, a 304 aa ECD that shares 98-99% amino acid identity with mouse, rat, canine and bovine IGSF4C, a 21 aa transmembrane sequence, and a 43 aa cytoplasmic domain. The apparent size of mouse or human IGSF4C may be variably reported as 48-67 kDa, probably due to differences in glycosylation (2, 5, 8). In the peripheral nervous system, IGSF4C is expressed on Schwann cells, and its internodal interaction with IGSF4A (Necl-1, SynCAM-3) on axons is critical for adhesion and myelination (6-8). In the brain, all IGSF4 family members are expressed at high levels concurrent with synapse formation (4). In the cerebellum, IGSF4C is expressed on Purkinje cells, with complementary expression of IGSF4 on granule cells (4). Heterophilic interaction with IGSF4D (Necl-3, SynCAM2) has also been identified, but homophilic interaction is unlikely (4, 6). IGSF4C is also proposed as a tumor suppressor that is downregulated in many prostate cancers and gliomas (1, 5).

1. Fukuhara, H. et al. (2001) Oncogene 20:5401.
2. Biederer, T. et al. (2006) Genomics 87:139.
3. Takai, Y. et al. (2008) Nat. Rev. Mol. Cell Biol. 9:603.
4. Thomas, L. A. et al. (2008) J. Comp. Neurol. 510:47.
5. Williams, Y. N. et al. (2005) Oncogene 25:1446.
6. Fogel, A. I. et al. (2007) J. Neurosci. 27:12516.
7. Spiegel, I. et al. (2007) Nat. Neurosci. 10:861.
8. Maurel, P. et al. (2007) J. Cell Biol. 178:861.

Bioinformatics

• Uniprot:
  • Q8NFZ8()